Total Current Liabilities
Regeneron Pharmaceuticals Total Current Liabilities increased by 16.9% to $5.11B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 43.2%, from $3.57B to $5.11B. Over 5 years (FY 2020 to FY 2025), Total Current Liabilities shows an upward trend with a 10.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A rising trend relative to current assets may indicate tightening liquidity or increased operational leverage.
Detailed definition
The sum of all financial obligations and debts that are due to be settled within one year or one operating cycle. This i...
Peer comparison
Used in the calculation of the Current Ratio and Quick Ratio to assess a firm's short-term financial health relative to industry peers.
total_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.73B | $3.71B | $3.93B | $3.01B | $3.03B | $2.88B | $3.14B | $3.10B | $3.10B | $3.60B | $3.42B | $3.58B | $3.51B | $3.66B | $3.94B | $3.57B | $3.67B | $4.43B | $4.37B | $5.11B |
| QoQ Change | — | -0.5% | +5.9% | -23.5% | +0.9% | -5.1% | +9.1% | -1.3% | +0.1% | +15.9% | -4.9% | +4.6% | -2.0% | +4.3% | +7.7% | -9.6% | +2.8% | +20.7% | -1.3% | +16.9% |
| YoY Change | — | — | — | — | -18.7% | -22.5% | -20.1% | +3.1% | +2.3% | +25.0% | +9.0% | +15.5% | +13.0% | +1.7% | +15.2% | -0.4% | +4.5% | +20.9% | +10.8% | +43.2% |
Total Current Liabilities at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's total current liabilities?
- Regeneron Pharmaceuticals (REGN) reported total current liabilities of $5.11B in Q1 2026.
- How has Regeneron Pharmaceuticals's total current liabilities changed year-over-year?
- Regeneron Pharmaceuticals's total current liabilities increased by 43.2% year-over-year, from $3.57B to $5.11B.
- What is the long-term trend for Regeneron Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total current liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $2.70B to $4.37B.
- What does total current liabilities mean?
- The total amount of money the company owes to others that is due within one year.